文献速递肾小球疾病遗传性与小管间质肾病肾移植

肾淀粉样变性谱系演变:诊断、分型与治疗进展

The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本文综述肾淀粉样变性的疾病谱,涵盖AL、AA、ALECT2及遗传性淀粉样变性,强调刚果红染色阳性后需免疫组化或质谱精准分型,治疗以抑制新纤维生成为核心,肾移植在获得缓解者中结局与一般移植人群相当。

要点

  • 肾淀粉样变性需刚果红染色阳性后以免疫组化或质谱精准鉴定纤维蛋白类型。
  • AL淀粉样变性治疗以化疗抑制克隆来源新纤维生成,遗传性形式可用基因沉默疗法。
  • 获得缓解的肾淀粉样变性患者行肾移植结局与一般移植人群相当。

核心结论

  • 肾淀粉样变性为多种错误折叠蛋白沉积所致异质性疾病谱,精准分型是诊断与治疗的关键。

研究设计与样本

  • 综述,总结肾淀粉样变性的诊断、分型与治疗进展。

主要发现

  • 西方国家肾淀粉样变性主要类型为免疫球蛋白轻链(AL)淀粉样变性,通常继发于浆细胞克隆,少数继发于B细胞克隆。
  • 较少见病因包括AA淀粉样变性、ALECT2及遗传性淀粉样变性。
  • 主要肾脏表现为肾病综合征和肾功能不全,蛋白尿可轻微或缺如。
  • 病程进展,许多患者肾脏生存和总体生存降低。
  • 所有类型淀粉样变性活检刚果红染色通常阳性,精准鉴定淀粉样纤维蛋白最佳方法为免疫组化或蛋白质组学研究如质谱。

临床怎么用

  • 肾活检刚果红染色阳性后应行免疫组化或质谱精准鉴定淀粉样纤维蛋白类型。
  • AL淀粉样变性以化疗抑制新淀粉样纤维生成,AA淀粉样变性控制炎症,遗传性形式如转甲状腺素蛋白相关者可用基因沉默疗法。
  • 获得缓解的肾淀粉样变性患者可考虑肾移植,结局与一般移植人群相当。
  • 新方法旨在增强天然淀粉样物清除以降低器官衰竭速率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney amyloidosis encompasses a spectrum of heterogeneous conditions in which damage is caused by the deposition of various misfolded proteins that aggregate into fibrils. The main form of renal amyloidosis in Western countries is immunoglobulin light chain (AL) amyloidosis, which is usually secondary to a plasma cell clone or less frequently a B-cell clone, while rarer causes include AA amyloidosis, ALECT2 and hereditary amyloidoses. The main renal manifestations include nephrotic syndrome and kidney dysfunction with modest or absent proteinuria. The course is progressive and renal and overall survival is reduced in many patients. While biopsies are usually positive by Congo Red staining in all types of amyloidosis, precise identification of the amyloid fibril protein is essential and is best achieved with immunohistochemistry or proteomic studies, such as mass spectrometry. This method also allows the discovery of novel amyloidogenic proteins and has contributed to expand the list of amyloid types. The current treatment strategy is based on suppressing new amyloid fibril production through chemotherapy in AL amyloidosis, control of inflammation in AA amyloidosis and 'gene silencing' therapies in hereditary forms, such as the one linked with transthyretin. Novel approaches aim at enhancing natural amyloid clearance in order to reduce the rate of organ failure. Kidney transplantation in patients who achieved response has shown outcomes comparable to the general transplant population. In this review, we present the key aspects of renal amyloidosis and discuss novel concepts in this evolving field.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Allinovi M, Trivioli G, Gaudio C, et al. The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment. Nephrol Dial Transplant. 2025. PMID: 40036358. doi:10.1093/ndt/gfaf042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。